| Magnetic nanoparticles have been highly regarded because of their unique properties, such
as hyperthermia, medicine control release, and diagnostic applications. The role of these
magnetic nanoparticles as medicine delivery carriers is bolder due to certain properties, in
addition to the usual properties of nanomaterials, The main aim of the current paper is to
offer a new system for the modification of Fe3
O4
(SPIONs) superparamagnetic nanoparticles
physically and chemically with polymers through physical retention. These modified
nanoparticles have been used to encapsulate cisplatin as an anticancer medicine and the
effect of nanocapsulated cisplatin has been studied in lung cancer (A549) cell line. Using ring-
opening polymerization Triblock copolymer PCL-PEG-PCL was prepared of ɛ-caprolactone
(PCL) in the presence of polyethylene glycol (PEG). Magnetic iron nanoparticles were also
prepared and identified. Using Fourier Transform Infrared Spectroscopy (FTIR), the bulk
features of the copolymers were determined. Nanoparticles loaded with Cisplatin have been
ready using the copolymer containing iron superparamagnetic nanoparticles via double
emulsion solvent evaporation method and evaluated for medicine entrapment efficiency (%),
the quantity of medicine, size, and surface morphology. Cytotoxic tests have been considered
using MTT assay method in lung carcinoma (A549)-treated cells. As well as, using scanning
electron microscopy, Fourier Transform Infrared Spectroscopy (FTIR) and X-ray powder
diffraction (XRD) the particles have been specified. The results of the study in vitro showed
that Fe3
O4
-PCL-PEG nanoparticles did not have a cytotoxic effect and were biocompatible.
The anti-proliferative effect of cisplatin encapsulated in magnetic nanoparticles was much
earlier faster than pure cisplatin and enhanced the decrease in IC50 rate significantly. The
results of the study demonstrated that nanocapsulated cisplatin had a significant cytotoxic
and anticancer effect in vitro of the lung cancer cell line and it can be concluded that this
approach has the ability to fail some of the main chemotherapy constraints and can be an
appropriate approach for future programs in the treatment of lung cancer. |